Back to search

Use of Probe Drugs as Predictors of Drug Metabolism in Humans

Data up to Jan 2025

Published1997
Citations83
References51

Total Citations Per Year

Abstract

References (51)

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

1994 • 958 citations

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

1994 • 749 citations

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

1993 • 652 citations

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1980 • 544 citations

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

1992 • 536 citations

Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1

1990 • 535 citations

Biochemistry and molecular biology of the human CYP2C subfamily

1994 • 534 citations

Geographical/Interracial Differences in Polymorphic Drug Oxidation

1995 • 431 citations

Noninvasive tests of CYP3A enzymes

1994 • 414 citations

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

1994 • 350 citations

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

1989 • 349 citations

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

1995 • 310 citations

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test

1994 • 291 citations

The use of caffeine for enzyme assays: A critical appraisal

1993 • 282 citations

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

1987 • 281 citations

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

1996 • 280 citations

Rifampin drastically reduces plasma concentrations and effects of oral midazolam

1996 • 238 citations

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

1988 • 199 citations

Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine

1990 • 196 citations

Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.

1995 • 187 citations

Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva

1994 • 179 citations

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*

1996 • 172 citations

Advances in Drug Metabolism in Man

1995 • 167 citations

“It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism

1995 • 162 citations

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

1982 • 160 citations

Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms*

1995 • 154 citations

Expression of cytochrome P450 3A in amphibian, rat, and human kidney

1992 • 149 citations

Extremely Rapid Hydroxylation of Debrisoquine

1985 • 144 citations

Assessment of Liver Metabolic Function

1994 • 138 citations

Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men

1993 • 137 citations

The erythromycin breath test predicts the clearance of midazolam*

1995 • 132 citations

The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease

1992 • 132 citations

Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations

1996 • 128 citations

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

1992 • 120 citations

Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1

1995 • 111 citations

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test

1994 • 107 citations

Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo*

1995 • 101 citations

The erythromycin breath test as a predictor of cyclosporine blood levels

1990 • 99 citations

Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population

1994 • 90 citations

Rapid detection of CYP2D6 null alleles by long distance-and multiplex-polymerase chain reaction

1996 • 86 citations

Drug Interactions and the Cytochrome P450 System

1995 • 86 citations

Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4.

1992 • 80 citations

Caffeine as a probe for CYP1A2 activity

1994 • 74 citations

Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation.

1995 • 71 citations

The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects

1990 • 64 citations

Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients

1992 • 58 citations

Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test

1994 • 57 citations

P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients

1994 • 54 citations

Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.

1995 • 37 citations

Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine*

1996 • 35 citations

Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan*

1996 • 25 citations

Cited By (0)

Loading...